Ascentage Pharma Group International American Depository Shares (AAPG)

FairStock Score: 20/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Buffett-style investor, I want a business with durable competitive advantages, honest accounting, and a margin of safety. Ascentage is a clinical-stage biotech with pipeline candidates—HQP1351, APG-2575, APG-115—but no proven commercial engine. Any moat would rest on patents and clinical data, not current economics. The numbers are grim. At the 2026-10-13 close of $15.06, FairStock calculates a P/E of -6.38, a P/B of 16.92, ROE of -236.63%, ROCE of -28.04%, and D/E of 3.70. The Piotroski F-Score is 0/9 and the Altman Z-Score is -2.75, signaling financial distress and poor fundamental momentum. Revenue and profit growth are unavailable, and the Lynch category is 'none' because only 0 years of filed results exist—not enough to judge a record. The $2.1B market cap is a bet on future approvals, not present cash flows. A beta of 0.67 and a 52-week range of $14.45 to $37.50 show the stock is near its low but still highly valued against book. Graham would demand a bargain and a balance sheet that can survive setbacks. Here, high leverage and negative returns mean the equity could be wiped out if trials or financing disappoint. I see no margin of safety at these figures. The FairStock Score of 20/100 reinforces caution. This looks like speculation, not investment-grade value.

In plain English: Ascentage Pharma is a clinical-stage biotech that develops treatments for cancers, hepatitis B, and age-related diseases. The business looks weak on the numbers: it is losing money, carries high debt, and shows poor accounting health. At $15.06, the shares look expensive compared with the company's accounting value and earnings, even though they are near the bottom of their 52-week range.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer